Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
DAWN Quote, Financials, Valuation and Earnings
Last price:
$8.35
Seasonality move
:
-5.26%
Day range:
$8.21 - $8.60
52-week range:
$5.64 - $13.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.40x
P/B ratio:
1.90x
Volume:
2.1M
Avg. volume:
2.8M
1-year change:
-39.57%
Market cap:
$856.3M
Revenue:
$131.2M
EPS (TTM):
-$1.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$37.8M | -$0.28 | 50.99% | -69.07% | $22.25 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.66% | -35.2% | $8.25 |
|
LNTH
Lantheus Holdings, Inc.
|
$364.5M | $1.27 | -5.46% | -29.39% | $80.93 |
|
MRSN
Mersana Therapeutics, Inc.
|
$13.7M | -$0.89 | -69.75% | -14.49% | $33.20 |
|
TVTX
Travere Therapeutics, Inc.
|
$106.1M | -$0.09 | 91.27% | -87.94% | $41.5000 |
|
XBIO
Xenetic Biosciences, Inc.
|
$631.9K | -- | 6.75% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$8.34 | $22.25 | $856.3M | -- | $0.00 | 0% | 6.40x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.21 | $8.25 | $877.3M | -- | $0.00 | 0% | 2.93x |
|
LNTH
Lantheus Holdings, Inc.
|
$59.77 | $80.93 | $4B | 25.10x | $0.00 | 0% | 2.73x |
|
MRSN
Mersana Therapeutics, Inc.
|
$27.85 | $33.20 | $138.8M | -- | $0.00 | 0% | 54.14x |
|
TVTX
Travere Therapeutics, Inc.
|
$34.8500 | $41.5000 | $3.1B | -- | $0.00 | 0% | 7.26x |
|
XBIO
Xenetic Biosciences, Inc.
|
$2.42 | -- | $5.5M | -- | $0.00 | 0% | 1.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
0.64% | 0.642 | 0.4% | 8.29x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
LNTH
Lantheus Holdings, Inc.
|
35.63% | -1.491 | 18.22% | 2.30x |
|
MRSN
Mersana Therapeutics, Inc.
|
-4.01% | -0.289 | 5.93% | 1.32x |
|
TVTX
Travere Therapeutics, Inc.
|
81.76% | 1.077 | 15.42% | 2.50x |
|
XBIO
Xenetic Biosciences, Inc.
|
-- | 3.604 | -- | 3.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$35.3M | -$24.3M | -30.8% | -30.98% | -60.94% | -$5.8M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
LNTH
Lantheus Holdings, Inc.
|
$222.4M | $43.6M | 9.52% | 14.66% | 11.36% | $94.7M |
|
MRSN
Mersana Therapeutics, Inc.
|
$10.9M | -$7.5M | -689.85% | -533.43% | -67.68% | -$3.2M |
|
TVTX
Travere Therapeutics, Inc.
|
$147.5M | $24.9M | -21.07% | -263.9% | 15.12% | -$871K |
|
XBIO
Xenetic Biosciences, Inc.
|
-- | -$544.7K | -59.39% | -59.39% | -53.04% | -$658.2K |
Day One Biopharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns DAWN or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -135.28%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About DAWN or IOVA?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 166.79%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 273.3%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Day One Biopharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Day One Biopharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is DAWN or IOVA More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock DAWN or IOVA?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or IOVA?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.40x versus 2.93x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.40x -- $39.8M -$19.7M IOVAIovance Biotherapeutics, Inc.2.93x -- $67.5M -$91.3M
-
Which has Higher Returns DAWN or LNTH?
Lantheus Holdings, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of 7.23%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B -
What do Analysts Say About DAWN or LNTH?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 166.79%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $80.93 which suggests that it could grow by 35.4%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 LNTHLantheus Holdings, Inc.8 3 0 -
Is DAWN or LNTH More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.102, suggesting its less volatile than the S&P 500 by 110.17%.
-
Which is a Better Dividend Stock DAWN or LNTH?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or LNTH?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 25.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.40x versus 2.73x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.40x -- $39.8M -$19.7M LNTHLantheus Holdings, Inc.2.73x 25.10x $384M $27.8M
-
Which has Higher Returns DAWN or MRSN?
Mersana Therapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -68.54%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Mersana Therapeutics, Inc.'s return on equity of -533.43%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M MRSNMersana Therapeutics, Inc.99.25% -$1.51 -$57.2M -
What do Analysts Say About DAWN or MRSN?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 166.79%. On the other hand Mersana Therapeutics, Inc. has an analysts' consensus of $33.20 which suggests that it could grow by 19.21%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Mersana Therapeutics, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Mersana Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 MRSNMersana Therapeutics, Inc.0 7 0 -
Is DAWN or MRSN More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mersana Therapeutics, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.856%.
-
Which is a Better Dividend Stock DAWN or MRSN?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Mersana Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or MRSN?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than Mersana Therapeutics, Inc. quarterly revenues of $11M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Mersana Therapeutics, Inc.'s net income of -$7.5M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Mersana Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.40x versus 54.14x for Mersana Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.40x -- $39.8M -$19.7M MRSNMersana Therapeutics, Inc.54.14x -- $11M -$7.5M
-
Which has Higher Returns DAWN or TVTX?
Travere Therapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of 15.59%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M TVTXTravere Therapeutics, Inc.89.46% $0.25 $403.3M -
What do Analysts Say About DAWN or TVTX?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 166.79%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Travere Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is DAWN or TVTX More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.
-
Which is a Better Dividend Stock DAWN or TVTX?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or TVTX?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.40x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.40x -- $39.8M -$19.7M TVTXTravere Therapeutics, Inc.7.26x -- $164.9M $25.7M
-
Which has Higher Returns DAWN or XBIO?
Xenetic Biosciences, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -49.65%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M XBIOXenetic Biosciences, Inc.-- -$0.33 $4M -
What do Analysts Say About DAWN or XBIO?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 166.79%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.89%. Given that Xenetic Biosciences, Inc. has higher upside potential than Day One Biopharmaceuticals, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Day One Biopharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 XBIOXenetic Biosciences, Inc.0 1 0 -
Is DAWN or XBIO More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.
-
Which is a Better Dividend Stock DAWN or XBIO?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or XBIO?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.40x versus 1.31x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.40x -- $39.8M -$19.7M XBIOXenetic Biosciences, Inc.1.31x -- $1M -$509.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
